Figure 8. PGRN levels and oligomerization are changed in human fibroblasts derived from individuals with and without GRN mutations.

(a,b) Immunoblots of media and lysates obtained from wild type (WT) or GRN mutant (MUT) human fibroblasts transfected with either control or PSAP siRNAs (a), or with either control or PSAP plasmids (b). (c,d) Quantification of PGRN immunoreactivity in media from WT or GRN mutant (MUT) human fibroblasts transfected with either control or PSAP siRNAs (c) or with either control or PSAP plasmids (d) (n=3 per group). (e,f) Immunoblot of BS³-crosslinked media obtained from WT or GRN mutant (MUT) human fibroblasts transfected with either control or PSAP siRNAs (e) or with either control or PSAP plasmids (f). Graphs represent the mean±s.e.m. *Differs from control-transfected cells of the same cell line, P<0.05, **P<0.01, ***P<0.001 by one-way ANOVAs.